CD19 and non-Hodgkin lymphoma: Out of the two clinical investigations that were conducted, only one has been published thus far (Table 2).Liu et al. utilized anti-CD19 CAR-NK cells from cord blood to treat 11 patients with relapsed/refractory CD19 + non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL).